Business Review for the nine months ended September 30, 2016
bioMérieux – First-Half 2016 Results
bioMérieux – Second-Quarter 2016 Business Review
bioMérieux enlarges its pathogen identification capability on VITEK® MS
With a database of more than 15,000 strains VITEK® MS improves clinical decision-making for infectious diseases
bioMerieux Receives FDA Clearance for Expanded Use of VIDAS® B•R•A•H•M•S PCT™ Test for Managing Sepsis Patients with Elevated Risk of Mortality
Tracking PCT – a biomarker for bacterial infections – over time provides strong indication of likely mortality, enabling physicians to personalize care for high-risk patients
bioMérieux acquires Hyglos
bioMérieux acquires Hyglos and expands its offering to the detection of endotoxins in pharmaceutical products
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1 Two joint research laboratories focused on a common goal: advancing medical research for the benefit of patients
bioMérieux and Antwerp University unveil the final results of the first Global Point Prevalence Survey1 of antibiotic use and resistance rates in hospitals
Huge discrepancies in antibiotic use practices between countries 2nd line antibiotics2 too frequently prescribed
FilmArray® Torch is now FDA cleared with all 4 existing FilmArray® Panels and the system gets CE marked
BioFire receives FDA clearances for FilmArray® Torch with FilmArray® Blood Culture Identification Panel, Gastrointestinal Panel and Meningitis/Encephalitis Panel FilmArray® Torch delivers high throughput, radically smaller footprint